PUBLISHED: Fri, 11 Jun 2021 20:17:24 GMT
June 11 (Reuters) – Novavax Inc said on Friday its COVID-19 vaccine candidate showed immune response and protection against the SARS-CoV-2 Beta variant, which was originally identified in South Africa, in three animal and human studies. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)
(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html
Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent. Sign up here.